Clinical trials
Locally Advanced Prostate Cancer clinical trials
Below are recruiting locally advanced prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 291 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06607939RecruitingPhase 1
Study of ORB-021 for advanced solid tumors
This trial tests a new drug called ORB-021 for people with advanced solid tumors that have come back or not responded to other treatments. The goal is to see if ORB-021 is safe and how it affects the body.
Scottsdale, ArizonaAges 18 years+ - NCT07241793RecruitingPhase 2
Trastuzumab rezetecan with or without immunotherapy for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT06659341RecruitingPhase 1
Study of BAY3498264 with Sotorasib for KRAS G12C Cancers
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Albury, New South WalesAges 18 years+ - NCT07293585RecruitingPhase 3
Precision radiation to protect erectile function in prostate cancer
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
Los Angeles, CaliforniaAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT06782555RecruitingPhase 1/Phase 2
Study of experimental drug combo for advanced cancers
This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.
Houston, TexasAges 18 years+ - NCT06567015RecruitingPhase 1/Phase 2
Study of a new drug for advanced lung cancer that stopped responding to current treatments
This trial tests a new medicine, STX-241, for people with a specific type of advanced lung cancer (NSCLC) that has stopped responding to current targeted therapies. The goal is to see if this new drug can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
St Louis, MissouriAges 18 years+ - NCT05661461RecruitingPhase 1
Test drug dosing and safety for advanced cancers with liver issues
This Phase 1 study tests different doses of nab-sirolimus to see if it is safe and how the body processes it. It is for people with advanced or metastatic solid tumors who also have moderate liver impairment.
San Antonio, TexasAges 18 years+ - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT06066437RecruitingPhase 1/Phase 2
Lutetium before prostate surgery for high-risk cancer
This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Houston, TexasAges 18 years+ - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT07455032RecruitingPhase 1
Neoadjuvant therapy combo for head and neck cancer
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07454642RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
Scottsdale, ArizonaAges 18 years+ - NCT07686445RecruitingPhase 1
Study of AN4035 for advanced cancers with RAS mutations
This trial tests a new drug, AN4035, for people with advanced cancers that have a RAS mutation and high levels of a protein called CEACAM5. The drug may help shrink tumors or slow their growth.
PerthAges 18 years+ - NCT05729646RecruitingPhase 2
Pre-surgery chemotherapy with toripalimab for dMMR stomach cancer
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
Hangzhou, ZhejiangAges 18–80 - NCT05866692RecruitingPhase 1
First-in-human capsule for advanced solid tumors
This Phase 1 study tests a new oral capsule (TY-2699a) in people with advanced or metastatic solid tumors that have limited treatment options. It will look for the safest dose and whether the drug can shrink tumors, especially in certain genetic/biomarker patterns.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05872685RecruitingPhase 2
Perioperative chemo plus serplulimab for specific stomach cancers
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
Hangzhou, ZhejiangAges 18–80 - NCT07847710RecruitingPhase 2
Combination therapy before and after surgery for early liver cancer
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
Nanjing, JiangsuAges 18–75 - NCT06449664Recruiting
Exercise program for men on hormone therapy for prostate cancer
This study tests whether a supervised exercise program can help men with prostate cancer stay stronger and feel better during combined radiation and hormone therapy. You may be able to join if you are about to start these treatments and are otherwise healthy enough to exercise.
StockholmAges 50–80
Hear when a new Locally Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced prostate cancer?
- Yes. Clin2 currently lists 291 recruiting locally advanced prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.